In short
Clinical trials are investigating Voxelotor in people with sickle cell disease. These studies look at whether it can improve markers of hemolysis, which means red blood cell breakdown, and help with organ damage. The trial data here focus on safety-related study design details, biological effects, and measured outcomes in a small patient group.
Key points
- Clinical trial data for Voxelotor show one Phase 2 study in people with sickle cell disease. The study was designed to test biological activity, especially whether it could improve intravascular hemolysis, which is red blood cell breakdown inside blood vessels. The main outcome was a drop of at least 20% in plasma hemoglobin from week 0 to week 48. This interventional study enrolled 35 participants and was completed. The trial title also suggests interest in possible improvement of organ damage.
Trial overview
The trial listed for Voxelotor is HEMolyse and Organ damage imPROvement in sickle cell disease by VoxElotor, with the study ID NCT05199766. It is a Phase 2, interventional study in sickle cell disease. The brief summary says the study aimed to evaluate the biological activity of Voxelotor on the reduction of intravascular hemolysis, measured by plasma hemoglobin.
Study population and design
The target population in this trial was people with sickle cell disease. The study used an intervention, meaning participants received the study treatment and the researchers measured the effects over time. The listed intervention was Oxbryta 500 mg film-coated tablets given by oral use, with a total dose shown in the source as 1500 mg.
The source does not provide extra details about age limits, sex limits, or other entry rules. Because of that, the only clearly stated participation group is people with sickle cell disease.
Outcomes and endpoints
The main endpoint, also called the primary outcome, was improvement of intravascular hemolysis. This was defined as at least a 20% decrease in plasma hemoglobin between week 0 and week 48.
In simple words, the researchers were checking whether a blood marker linked to red blood cell breakdown got better during the study. The trial title also mentions organ damage improvement, which suggests the researchers were interested in whether the treatment might help with damage caused by the disease.
Trial status and enrollment
This study is marked as Completed. The enrollment was 35 participants. That is a small study, which is common in early clinical research when the goal is to look for signs of biological effect.
What this trial means for patients
For patients, this trial is important because it tested whether Voxelotor could change a measurable sign of disease activity in sickle cell disease. The study did not focus on a broad range of conditions; it focused on one disease group and one main blood-based outcome. The available data are centered on study design, patient group, and measured results, rather than on a full list of clinical benefits or harms.